{"id":7619,"date":"2015-11-27T16:02:07","date_gmt":"2015-11-27T16:02:07","guid":{"rendered":"\/?p=7619"},"modified":"2015-11-27T16:14:47","modified_gmt":"2015-11-27T16:14:47","slug":"decision-diagnostics-corp-otcmktsdecn-soldiers-on","status":"publish","type":"post","link":"\/articles\/decision-diagnostics-corp-otcmktsdecn-soldiers-on\/","title":{"rendered":"Decision Diagnostics Corp (OTCMKTS:DECN) Soldiers On"},"content":{"rendered":"\n

Some of you will open Decision Diagnostics Corp (OTCMKTS:DECN<\/a>)’s latest financial statement and they’ll probably think that the company has come a long way. They’ll see that the Q3 revenues are almost 500% up from on the ones logged twelve months ago and they’ll also see that the long lasting legal struggles with Johnson & Johnson might finally be coming to an end. In fact, DECN<\/a><\/strong> say in the report that they’re preparing themselves for the final dismissal of the patent infringement claims filed by the medical giant, and that they’ll then proceed to look for the damages made by the whole proceedings. <\/p>\n

Investors have certainly read these parts of the latest report and they’re loving them. The statement came out last week and although there was a brief moment of hesitation at the beginning, the ticker eventually stabilized and began climbing. Six consecutive green sessions later, it reached a close of $0.17 for the first time in almost exactly five months.<\/p>\n

So, people have taken a quick look at the report and they seem to like what they see. The Thanksgiving holiday, however, should give them a chance to look through the statement in more detail which probably isn’t such a bad call as it might give them an inside into some interesting details.<\/p>\n

The first one is eye-achingly obvious. Despite the impressive revenue jump, DECN<\/a><\/strong>‘s financials are far from ideal:<\/p>\n